Glesatinib

Drug Profile

Glesatinib

Alternative Names: MGCD-265

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator MethylGene
  • Developer MethylGene; Mirati Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c met inhibitors; RON protein inhibitors; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Head and neck cancer

Most Recent Events

  • 09 Mar 2017 Efficacy data from a phase I/II trial in Solid tumours released by Mirati Therapeutics
  • 05 Jan 2017 Efficacy data from phase I trial in Solid tumours released by Mirati Therapeutics
  • 05 Jan 2017 Efficacy data from phase II trial AMETHYST in Non-small cell lung cancer released by Mirati Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top